Home Biosimilar Antibodies Immunology & Inflammation CD markers Otelixizumab (Anti-CD3)
For research use only. Not for use in humans.

Otelixizumab (Anti-CD3)

Synonyms: ChAglyCD3

Otelixizumab (Anti-CD3) is a human monoclonal antibody targeting CD3. It can be used for the research of type 1 diabetes. MW :145.14 KD.

Otelixizumab (Anti-CD3)

Quality Control

Batch: A300401 Purity: 99% Protein concentration: 11.61mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Otelixizumab (Anti-CD3) is a human monoclonal antibody targeting CD3. It can be used for the research of type 1 diabetes. MW :145.14 KD.
References

Product Details

CAS No. 881191-44-2
Isotype Human IgG1
Source CHO
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05828511 RECRUITING Drug: Linvoseltamab Multiple Myeloma Regeneron Pharmaceuticals 2023-12-19 PHASE1; PHASE2
NCT06669247 RECRUITING Drug: Linvoseltamab|Drug: REGN7945+Linvoseltamab Relapsed/Refractory Multiple Myeloma Regeneron Pharmaceuticals 2024-12-11 PHASE1; PHASE2
NCT07455851 RECRUITING Drug: Linvoseltamab|Drug: REGN17372+Linvoseltamab Relapsed Refractory Multiple Myeloma (RRMM) Regeneron Pharmaceuticals 2026-03-26 PHASE1; PHASE2
NCT05730036 RECRUITING Drug: Linvoseltamab|Drug: Elotuzumab|Drug: Pomalidomide|Drug Relapsed Refractory Multiple Myeloma (RRMM) Regeneron Pharmaceuticals 2023-09-18 PHASE3
NCT03761108 RECRUITING Drug: Linvoseltamab Multiple Myeloma Regeneron Pharmaceuticals 2019-01-23 PHASE1; PHASE2
NCT06149286 RECRUITING Drug: Odronextamab|Drug: Lenalidomide|Drug: Rituximab Relapsed/Refractory Follicular Lymphoma; Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) Regeneron Pharmaceuticals 2023-12-28 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-05-13)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.